简介:EDITOR'SNOTE:Thereareabout83milliondisabledpeopleinChina,accountingfor6.34%ofthetotalpopulation,accordingtoanationalsurveyin2006.Asadisadvantagedgroup,therightsandinterestsofthedisabledarearousingmoreconcernsfromallwalksofsocietyinthecountry.FollowingisHumanRights'interviewwithShenZhifei,deputygeneraldirectoroftheChinaDisabledPersons'Federation,onthelegalguaranteeofthespecialgroup'srightsandinterests,theirrehabilitation,educationandemployment.
简介:Humanleukocyteantigen(HLA)systemisthemostpolymorphicregionknowninthehumangenome.Inthepresentstudy,weanalyzedforthefirsttimetheHLA-Agenepolymorphismsdefinedbythehigh-resolutiontypingmethods-sequence-basedtyping(SBT)in161NorthernChineseHanpeople.Atotalof74differentHLA-Agenetypesand36allelesweredetected.ThemostfrequentalleleswereA110101(GF=0.2360),A24020101(GF=0.1646),andA020101(GF=0.1553);followedbyA3303(GF=0.1180),A3001(GF=0.0590),andA310102(GF=0.0404).Thefrequenciesoffollowingalleles,A0203,A0205,A0206,A0207,A030101,A2423,A2601,A3201,andA3301,areallhigherthan0.0093.ThehomozygousallelesincludeA020101,A110101,A24020101andA310102.Heterozygosity(H),polymorphisminformationcontent(PIC),discriminationpower(DP)andprobabilityofpaternityexclusion(PPE)ofHLA-Ainthesampleswerecalculatedandtheirvalueswere0.8705,0.8491,0.6014,and0.9475,respectively.Hanpopulation,especiallytheallelesubtypescharacter,willbeofgreatinterestforclinicaltransplantation,disease-associatedstudyandforensicidentification.Implementationofhigh-resolutiontypingmethodsallowsasignificantlywiderspectrumofHLAvariationincludingrarealleles.Thisrpectrumwillfurtherbeextensivelyutilizedinmanyfields.
简介:AbstractBackground:HIV/AIDS has transformed into a chronic controllable but not yet curable infectious disease as other chronic diseases to some extent. The additional of so called fourth 90% that included the improved health-related quality of life (HRQoL) for people living with HIV (PLWHIV) required solutions beyond antiretroviral therapy and viral load suppression. This study will explore the role of personality, social economic and prevention strategy effection on HRQoL among people living with HIV/AIDS.Methods:A cross-sectional study was conducted among PLWHIV aged more than 16 years old in the 10 municipalities in Yunnan Province, China from October 2019 to May 2020, enrolling total 1997 participants. Individual-level HRQoL data were measured by 12-item Short Form Health Survey (SF-12) and EuroQol Five Dimensions Questionnaire (EQ-5D-5L). We assembled municipal-level data about social economic from Yunnan Statistical Yearbook in 2020 and strategy practice information from the self-evaluation system. We used the principal component analysis to build the social economic and strategy effect on each area respectively and one-way ANOVA was used to perform univariate analysis to identify the predictors with significant differences. Finally we used multi-level model (MLM) to explore the personality, social economic and strategy effects in health-related quality of life among PLWHIV.Results:The global score for quality of life measured using EQ-5D-5L had an estimated mean score (standard deviation, SD) of 0.901 ± 0.146. The HRQoL score measured using PCS-12 had an estimated mean score (SD) of 46.62 ± 8.55. The mean MCS-12 score (SD) was estimated to be 47.80 ± 9.71 . The area-level predictors explained a proportion of 13.6-17.2% for the between-area variation of the HRQoL scores, regardless of the total HRQoL, physical component and mental component. The impacts of stigma (P < 0.01), social support (P < 0.001), anxiety (P < 0.001), depression (P < 0.05) and social economic status (P < 0.05) on HRQoL at the individual-level were significantly different. The plots visualized the impact of individual-level factors on a respondent’s HRQoL was modified by the area-level characteristics.Conclusions:The study identified the possible strategy determinant of individual HRQoL of PLWHIV and also the area effect on HRQoL. Stigma, social support, anxiety, depression and social economic status were the individual-level determinants on HRQoL. These could be a valuable resource for evaluating the overall health of the areas and help improve local decision making.
简介:正TheUnderstandingandCooperationDialogue,SponsoredbytheChineseAssociationforInternationalUnderstanding(CAFIU)andtheChinaFoundationforPeaceandDevelopment(CFPD),andCo-organizedbytheChinesePeople'sAssociationforPeaceandDisarmament
简介:Thegenesfor5-lipoxygenaseactivatingprotein(ALOX5AP)andphosphodiesterase4D(PDE4D)havebeendemonstratedassusceptibilitygenesforlacunarintheIcelandicandPakistanipopulations,butlittleisknownabouttheroleofthesegenesinChinesepopulations.Thepresentstudyutilizedpolymerasechainreactionandligasedetectionreactiontodetectsinglenucleotidepolymorphisms(SNPs)in280consecutivestrokepatientsand258unrelatedpopulation-basedcontrolsfromNanjing,JiangsuProvince,China.Theallelefrequency,genotypes,andhaplotypesofthetwoSNPs(rs456009andrs966221)inPDE4Dweresimilarbetweenthetwogroups.However,Aallelefrequencyofrs4073259(A/G)andrs4769055(A/C)intheALOX5APgeneexhibiteddifferencesintwogroups,andespeciallythehaplotypeoftheSNPwassignificantlydifferentbetweenthetwogroups.ResultssuggestedthattheALOX5APgenemightbeinvolvedinlacunarinfarct,whilePDE4DgenewasnotariskfactorforlacunarinfarctinindividualsfromJiangsuProvince,China.
简介:AbstractBackground:Numerous studies have focused on lymphoma among patients infected with human immunodeficiency virus (HIV). However, little is known about the treatment options and survival rate of lymphoma in the Chinese people living with HIV (PLHIV). Our study aimed to investigate the prognosis and compare outcome of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab(R-CHOP) as front line therapy for PLHIV with diffuse large B-cell lymphoma (DLBCL) receiving modern combined antiretroviral therapy (cART).Methods:A retrospective analysis evaluating PLHIV with DLBCL was performed in Shanghai Public Health Clinical Center from July 2012 to September 2019. The demographic and clinical data were collected, and overall survival (OS) and progression-free survival (PFS) analyses of patients receiving R-CHOP or DA-EPOCH-R therapy were performed by Kaplan-Meier analysis. Additionally, a Cox multiple regression model was constructed to identify related factors for OS.Results:A total of 54 eligible patients were included in the final analysis with a median follow-up of 14 months (interquartile range [IQR]: 8-29 months). The proportion of high international prognostic index (IPI) patients was much larger in the DA-EPOCH-R group (n = 29) than that in the R-CHOP group (n = 25). The CD4 cell counts and HIV RNA levels were not significantly different between the two groups. The 2-year OS for all patients was 73%. However, OS was not significantly different between the two groups, with a 2-year OS rate of 78% for the DA-EPOCH-R group and 66% for the R-CHOP group. Only an IPI greater than 3 was associated with a decrease in OS, with a hazard ratio of 5.0. The occurrence of grade 3 and 4 adverse events of chemotherapy was not significantly different between the two groups.Conclusions:Outcomes of R-CHOP therapy do not differ from those of DA-EPOCH-R therapy. No HIV-related factors were found to be associated with the OS of PLHIV in the modern cART era.
简介:<正>Theauthorregrets〈Thecorrectedtitleshouldbe"Peoplecanlivelongerbyhavingmorephysicalactivity"〉.